collection
https://read.qxmd.com/read/29497819/cimpact-now-update-2-diagnostic-clarifications-for-diffuse-midline-glioma-h3-k27m-mutant-and-diffuse-astrocytoma-anaplastic-astrocytoma-idh-mutant
#1
LETTER
David N Louis, Caterina Giannini, David Capper, Werner Paulus, Dominique Figarella-Branger, M Beatriz Lopes, Tracy T Batchelor, J Gregory Cairncross, Martin van den Bent, Wolfgang Wick, Pieter Wesseling
No abstract text is available yet for this article.
April 2018: Acta Neuropathologica
https://read.qxmd.com/read/31996992/cimpact-now-update-5-recommended-grading-criteria-and-terminologies-for-idh-mutant-astrocytomas
#2
JOURNAL ARTICLE
Daniel J Brat, Kenneth Aldape, Howard Colman, Dominique Figrarella-Branger, Gregory N Fuller, Caterina Giannini, Eric C Holland, Robert B Jenkins, Bette Kleinschmidt-DeMasters, Takashi Komori, Johan M Kros, David N Louis, Catriona McLean, Arie Perry, Guido Reifenberger, Chitra Sarkar, Roger Stupp, Martin J van den Bent, Andreas von Deimling, Michael Weller
No abstract text is available yet for this article.
March 2020: Acta Neuropathologica
https://read.qxmd.com/read/32307792/cimpact-now-update-6-new-entity-and-diagnostic-principle-recommendations-of-the-cimpact-utrecht-meeting-on-future-cns-tumor-classification-and-grading
#3
JOURNAL ARTICLE
David N Louis, Pieter Wesseling, Kenneth Aldape, Daniel J Brat, David Capper, Ian A Cree, Charles Eberhart, Dominique Figarella-Branger, Maryam Fouladi, Gregory N Fuller, Caterina Giannini, Christine Haberler, Cynthia Hawkins, Takashi Komori, Johan M Kros, H K Ng, Brent A Orr, Sung-Hye Park, Werner Paulus, Arie Perry, Torsten Pietsch, Guido Reifenberger, Marc Rosenblum, Brian Rous, Felix Sahm, Chitra Sarkar, David A Solomon, Uri Tabori, Martin J van den Bent, Andreas von Deimling, Michael Weller, Valerie A White, David W Ellison
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT-NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification...
July 2020: Brain Pathology
https://read.qxmd.com/read/31297242/how-we-treat-glioblastoma
#4
REVIEW
Michael Weller, Emilie Le Rhun, Matthias Preusser, Jörg-Christian Tonn, Patrick Roth
Glioblastoma is an intrinsic brain tumour thought to arise from neuroglial progenitor cells. Its incidence increases steadily with age. Males are moderately more often affected. Genetic predisposition and exposure to irradiation in childhood are the only established risk factors which, however, account only for a very small proportion of glioblastomas. Surgery as safely feasible not only to allow for tissue diagnosis but also to reduce tumour volume is usually the first therapeutic measure. Radiotherapy delivered to the tumour region with a safety margin has been demonstrated to roughly double survival four decades ago...
2019: ESMO Open
https://read.qxmd.com/read/29261148/advances-in-brain-tumor-surgery-for-glioblastoma-in-adults
#5
REVIEW
Montserrat Lara-Velazquez, Rawan Al-Kharboosh, Stephanie Jeanneret, Carla Vazquez-Ramos, Deependra Mahato, Daryoush Tavanaiepour, Gazanfar Rahmathulla, Alfredo Quinones-Hinojosa
Glioblastoma (GBM) is the most common primary intracranial neoplasia, and is characterized by its extremely poor prognosis. Despite maximum surgery, chemotherapy, and radiation, the histological heterogeneity of GBM makes total eradication impossible, due to residual cancer cells invading the parenchyma, which is not otherwise seen in radiographic images. Even with gross total resection, the heterogeneity and the dormant nature of brain tumor initiating cells allow for therapeutic evasion, contributing to its recurrence and malignant progression, and severely impacting survival...
December 20, 2017: Brain Sciences
https://read.qxmd.com/read/27557526/gliadel-wafer-implantation-combined-with-standard-radiotherapy-and-concurrent-followed-by-adjuvant-temozolomide-for-treatment-of-newly-diagnosed-high-grade-glioma-a-systematic-literature-review
#6
REVIEW
Lynn S Ashby, Kris A Smith, Baldassarre Stea
Since 2003, only two chemotherapeutic agents, evaluated in phase III trials, have been approved by the US Food and Drug Administration for treatment of newly diagnosed high-grade glioma (HGG): Gliadel wafers (intracranially implanted local chemotherapy) and temozolomide (TMZ) (systemic chemotherapy). Neither agent is curative, but each has been shown to improve median overall survival (OS) compared to radiotherapy (RT) alone. To date, no phase III trial has tested these agents when used in sequential combination; however, a number of smaller trials have reported favorable results...
August 24, 2016: World Journal of Surgical Oncology
https://read.qxmd.com/read/27617697/the-epithelial-to-mesenchymal-transition-like-process-in-glioblastoma-an-updated-systematic-review-and-in-silico-investigation
#7
REVIEW
Isabele C Iser, Mariana B Pereira, Guido Lenz, Márcia R Wink
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer due to its highly invasive nature that impedes the surgical removal of all tumor cells, making relapse inevitable. However, the mechanisms used by glioma cells to invade the surrounding tissue are still unclear. In this context, epithelial-to-mesenchymal transition (EMT) has emerged as a key regulator of this invasive state and although the real relevance of this program in malignant glioma is still controversial, it has been strongly associated with GBM malignancy...
March 2017: Medicinal Research Reviews
https://read.qxmd.com/read/28475720/developing-an-algorithm-for-optimizing-care-of-elderly-patients-with-glioblastoma
#8
JOURNAL ARTICLE
Patrick M Flanigan, Arman Jahangiri, Ruby Kuang, Albert Truong, Sarah Choi, Alvin Chou, Annette M Molinaro, Michael W McDermott, Mitchel S Berger, Manish K Aghi
BACKGROUND: Elderly patients with glioblastoma have an especially poor prognosis; optimizing their medical and surgical care remains of paramount importance. OBJECTIVE: To investigate patient and treatment characteristics of elderly vs nonelderly patients and develop an algorithm to predict elderly patients' survival. METHODS: Retrospective analysis of 554 patients (mean age = 60.8; 42.0% female) undergoing first glioblastoma resection or biopsy at our institution (2005-2011)...
January 1, 2018: Neurosurgery
https://read.qxmd.com/read/28379424/combination-therapy-with-potent-pi3k-and-mapk-inhibitors-overcomes-adaptive-kinome-resistance-to-single-agents-in-preclinical-models-of-glioblastoma
#9
JOURNAL ARTICLE
Robert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, Harshil D Dhruv, David M Irvin, Ryan E Bash, Steven P Angus, Laura E Herring, Jeremy M Simon, Kasey R Skinner, Juanita C Limas, Xin Chen, Ralf S Schmid, Marni B Siegel, Amanda E D Van Swearingen, Michael J Hadler, Erik P Sulman, Jann N Sarkaria, Carey K Anders, Lee M Graves, Michael E Berens, Gary L Johnson, C Ryan Miller
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) effectors of receptor tyrosine kinase (RTK) signaling represent promising candidates. Methods: We previously developed a non-germline genetically engineered mouse model of GBM in which PI3K and MAPK are activated via Pten deletion and KrasG12D in immortalized astrocytes...
October 19, 2017: Neuro-oncology
https://read.qxmd.com/read/28467882/fluorescein-guidance-in-glioblastoma-resection
#10
JOURNAL ARTICLE
David W Roberts, Jonathan Olson
A 55-year-old man presented to the emergency department with a 1-week history of severe headache. Magnetic resonance imaging of the brain with and without gadolinium-based contrast agent revealed a rim-enhancing mass (4.5 cm in diameter) in the right temporal lobe. At the time of surgery for tumor..
May 4, 2017: New England Journal of Medicine
https://read.qxmd.com/read/28145904/overcoming-therapeutic-resistance-in-glioblastoma-the-way-forward
#11
REVIEW
Satoru Osuka, Erwin G Van Meir
Glioblastoma is the most common and lethal primary malignant brain tumor in adults. Patients die from recurrent tumors that have become resistant to therapy. New strategies are needed to design future therapies that target resistant cells. Recent genomic studies have unveiled the complexity of tumor heterogeneity in glioblastoma and provide new insights into the genomic landscape of tumor cells that survive and initiate tumor recurrence. Resistant cells also co-opt developmental pathways and display stem-like properties; hence we propose to name them recurrence-initiating stem-like cancer (RISC) cells...
February 1, 2017: Journal of Clinical Investigation
https://read.qxmd.com/read/25670220/new-strategies-in-glioblastoma-exploiting-the-new-biology
#12
REVIEW
Howard A Fine
Glioblastoma is one of the deadliest human cancers. There have been few significant therapeutic advances in the field over the past two decades, with median survival of only about 15 months despite aggressive neurosurgery, radiotherapy, and chemotherapy. Nevertheless, the past 5 years has seen an explosion in our understanding of the genetic and molecular underpinnings of these tumors, leading to renewed optimism about potential new therapeutic approaches. Several of the most promising new approaches include oncogenic signal transduction inhibition, angiogenesis inhibition, targeting canonical stem cell pathways in glioblastoma stem cells, and immunotherapy...
May 1, 2015: Clinical Cancer Research
https://read.qxmd.com/read/24981259/brain-cancer-intratumoural-heterogeneity-in-primary-glioblastoma
#13
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
August 2014: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/2720563/prognostic-factors-and-results-of-therapy-for-adult-thalamic-and-brainstem-tumors
#14
JOURNAL ARTICLE
P W Grigsby, D M Garcia, J R Simpson, B B Fineberg, H G Schwartz
This report is a retrospective analysis of 83 adults (greater than 16 years of age) with histologically proven or presumed primary neoplasms of the thalamus, hypothalamus, midbrain, pons, and medulla. Patients were treated with combined surgery and postoperative irradiation or with irradiation alone at the Washington University Medical Center (St. Louis, MO) from January 1950 through December 1984. Histologic analysis confirmed the diagnosis of tumor in 21, including nine with well-differentiated astrocytoma, four with astrocytoma with anaplasia, and eight with glioblastoma multiforme...
June 1, 1989: Cancer
https://read.qxmd.com/read/9202774/thalamic-gliomas-a-clinicopathologic-analysis-of-20-cases-with-reference-to-patient-age
#15
JOURNAL ARTICLE
S Nishio, T Morioka, S Suzuki, I Takeshita, M Fukui
Twenty patients (M 11, F9; ranging from 1-77 years old) with histologically proven glial tumours in the thalamic region, treated from 1979 until 1994 at Kyushu University Hospital were retrospectively reviewed and analysed in order to elucidate their clinical and neuropathological characteristics. The initial common clinical manifestations were those of increased intracranial pressure or motor weakness. The histological diagnosis of the tumour was pilocytic astrocytoma in 2 patients, fibrillary astrocytoma in 7, anaplastic astrocytoma in 7, and glioblastoma multiforme in 4...
1997: Acta Neurochirurgica
https://read.qxmd.com/read/2984910/surgical-approach-to-large-thalamic-gliomas
#16
JOURNAL ARTICLE
B Prakash
Fifteen cases of large thalamic gliomas were treated by laser surgery and CUSA under X8 magnification and subsequently they were subjected to radiotherapy. More than 50% of the tumours were located in the dominant hemisphere and therefore an interhemispheric approach was carried out to avoid disturbances of speech and field defects. Nine patients had astrocytomas grade II and the remaining six had astrocytomas grades III-IV. The quality and survival has been gratifying in the less malignant gliomas. The operative technique and use of Laser and CUSA is highlighted...
1985: Acta Neurochirurgica
https://read.qxmd.com/read/11214625/thalamic-astrocytomas-surgical-anatomy-and-results-of-a-pilot-series-using-maximum-microsurgical-removal
#17
JOURNAL ARTICLE
H J Steiger, C Götz, R Schmid-Elsaesser, W Stummer
Deep-seated astrocytomas within the basal ganglia and the thalamus are considered unfavourable for microsurgical removal since the circumferential neighbourhood of critical structures limits radical resection. On closer assessment, the thalamus has a unique configuration within the basal ganglia. Its tetrahedric shape has 3 free surfaces and only the ventrolateral border is in contact with vital and critical functional structures, e.g. the subthalamic nuclei and the internal capsule. The purpose of the present study was to investigate the feasibility of maximum microsurgical removal in a series of intrinsic thalamic astrocytomas...
2000: Acta Neurochirurgica
https://read.qxmd.com/read/2537807/multivariate-analysis-of-prognostic-factors-in-pediatric-and-adult-thalamic-and-brainstem-tumors
#18
JOURNAL ARTICLE
P W Grigsby, P R Thomas, H G Schwartz, B B Fineberg
A multivariate analysis of prognostic variables was performed on a retrospective review of 136 patients with presumed or histologically proven primary lesions of the thalamus and brainstem treated by combined surgery and post-operative irradiation or by irradiation alone from January 1950 through December 1983. Overall survival for all patients at 5 and 10 years was 34.4 and 27.8%, respectively. Follow-up of 33 living patients ranged from 3 to 22 years. Prognostic variables analyzed by univariate analysis and found to be of significance (p less than 0...
March 1989: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/16951965/thalamic-gliomas-in-children-an-extensive-clinical-neuroradiological-and-pathological-study-of-14-cases
#19
JOURNAL ARTICLE
Carla Fernandez, André Maues de Paula, Carole Colin, Benoît Quilichini, Corinne Bouvier-Labit, Nadine Girard, Didier Scavarda, Gabriel Lena, Dominique Figarella-Branger
OBJECT: Thalamic tumors represent only 1 to 5% of brain neoplasms but frequently affect children. However, pediatric series are rare and go back to several years in spite of recent advances in the neuroradiological, pathological, and molecular fields. METHODS: We report a series of 14 pediatric thalamic gliomas with clinical, neuroradiological, and pathological studies including p53 immunostaining in 11 cases and 1p19q status in three cases. RESULTS: Our series included five pilocytic astrocytomas, seven oligodendrogliomas, and two glioblastomas...
December 2006: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://read.qxmd.com/read/24285547/h3f3a-k27m-mutations-in-thalamic-gliomas-from-young-adult-patients
#20
JOURNAL ARTICLE
Koki Aihara, Akitake Mukasa, Kengo Gotoh, Kuniaki Saito, Genta Nagae, Shingo Tsuji, Kenji Tatsuno, Shogo Yamamoto, Shunsaku Takayanagi, Yoshitaka Narita, Soichiro Shibui, Hiroyuki Aburatani, Nobuhito Saito
INTRODUCTION: Mutations in H3F3A, which encodes histone H3.3, commonly occur in pediatric glioblastoma. Additionally, H3F3A K27M substitutions occur in gliomas that arise at midline locations (eg, pons, thalamus, spine); moreover, this substitution occurs mainly in tumors in children and adolescents. Here, we sought to determine the association between H3F3A mutations and adult thalamic glioma. METHODS: Genomic H3F3A was sequenced from 20 separate thalamic gliomas...
January 2014: Neuro-oncology
label_collection
label_collection
4724
1
2
2016-06-25 08:23:56
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.